The U.S. Food and Drug Administration has released a new draft guidance, “Safety Assessment of Genome Editing in Human Gene Therapy Products Using Next-Generation Sequencing,” providing a clearer, more structured framework for evaluating the safety of genome editing therapies. At the center of this guidance is a strong and explicit recommendation: next-generation sequencing (NGS) should be the foundation for assessing genomic risk.

Why NGS is now essential for genome editing programs

Genome editing technologies such as CRISPR, TALENs, and other platforms offer tremendous therapeutic potential. However, unintended edits—particularly off-target modifications and large-scale genomic alterations—remain a primary safety concern.

The FDA’s guidance reinforces that traditional analytical approaches are no longer sufficient on their own. Instead, NGS-based methods are positioned as the most comprehensive and scientifically robust tools for:

• Detecting off-target editing events across the genome
• Assessing chromosomal rearrangements and structural variants
• Evaluating insertion/deletion mutations (indels)
• Monitoring overall genomic integrity

This reflects a broader regulatory shift toward high-resolution, genome-wide characterization methods that can support confident safety assessments in both preclinical and clinical development.

Key NGS recommendations from the guidance

The draft guidance goes beyond general endorsement and provides detailed, actionable recommendations on how NGS should be implemented.

1. Sequencing strategy selection
Sponsors are encouraged to use a combination of targeted and genome-wide sequencing approaches. Targeted methods (e.g., amplicon sequencing) can quantify known or predicted off-target sites, while unbiased genome-wide approaches help identify unexpected edits.

2. Sample selection and study design
The FDA emphasizes analyzing biologically relevant samples, including edited cells and appropriate controls. Both ex vivo and in vivo editing scenarios must be considered, with study designs tailored to capture potential risks specific to each modality.

3. Depth and sensitivity requirements
NGS assays must be sufficiently sensitive to detect rare off-target events. This includes careful consideration of sequencing depth, error rates, and assay limitations to ensure meaningful detection thresholds.

4. Bioinformatics and data analysis
Robust computational pipelines are essential. The FDA highlights the importance of validated bioinformatics workflows capable of accurately identifying mutations, structural variants, and low-frequency events while minimizing false positives.

5. Reporting and regulatory alignment
Clear, transparent reporting of methods, parameters, and results is required to support regulatory submissions, including INDs and BLAs. The agency expects sponsors to justify their analytical approaches and demonstrate that their NGS strategies are fit for purpose.

Supporting both ex vivo and in vivo therapies

Importantly, the guidance applies to both:

Ex vivo gene editing, where cells are modified outside the body and then reintroduced
In vivo gene editing, where editing occurs directly within patient tissues

In both cases, NGS is positioned as a critical tool for understanding how editing behaves in real biological systems, not just under controlled laboratory conditions.

A more defined regulatory path forward

This draft guidance builds on prior FDA efforts and aligns with its broader initiative to accelerate the development of therapies for rare and ultra-rare diseases. By standardizing expectations around NGS-based safety assessment, the agency is providing sponsors with a clearer path to:

• Design studies that meet regulatory expectations
• Generate submission-ready data packages
• Reduce uncertainty during IND and BLA review processes

The emphasis on early engagement—through mechanisms such as INTERACT and pre-IND meetings—further underscores the FDA’s intent to collaborate with developers and ensure that NGS strategies are appropriately designed from the outset.

What this means for developers

For companies developing genome editing therapies, the message is direct: NGS is no longer optional, it is foundational.

Sponsors should be prepared to:

• Integrate NGS early in development programs
• Combine multiple sequencing approaches for comprehensive coverage
• Invest in validated bioinformatics pipelines
• Align assay design with regulatory expectations

Those who do so will be better positioned to de-risk their programs, generate high-quality safety data, and move more efficiently through the regulatory process.

Conclusion

The FDA’s latest draft guidance firmly establishes next-generation sequencing as the cornerstone of genome editing safety assessment. By providing detailed recommendations on sequencing strategies, analysis, and reporting, the agency is helping to standardize how genomic risks are evaluated.

For the field of gene therapy, this represents a meaningful step forward—bringing greater clarity, consistency, and confidence to the development of therapies designed to treat some of the most challenging diseases.

References

FDA News Release – FDA Issues Draft Guidance on Genome Editing Safety Standards to Advance Gene Therapy Development

FDA Draft Guidance for Industry – Safety Assessment of Genome Editing in Human Gene Therapy Products Using Next-Generation Sequencing